FANNIN PARTNERS LLC
4A10, a chimeric monoclonal antibody targeting IL-7 receptor (CD127) for treatment of relapsed T-cell acute lymphoblastic leukemia
- Sector
- Biotech
- Headquarters
- Houston, TX
- Founded
- 2014
- Latest Form D
- Dec 2018
- Total capital
- $19.2M
- Federal grants
- $15.3M
- 28 awards · 2017–2025
- Rank in peer group#156 of 514
- Private capital raised
- $4M
- 3 Form D · last Dec 2018
- 94 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 3 pending · first 2019
- Rank in peer group#85 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Developing Scg3 Raptamers as a novel targeted therapy for wet AMD$300K
- Federal grantHealth and Human S · Phase II · Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$1.0M
- Federal grantHealth and Human S · Phase I · Investigation of a Novel PDE4B Inhibitor for Stimulant Use Disorder$320K
- Federal grantHealth and Human S · Phase I · Bedside right-heart catheterization for early diagnosis and more effective management of patients with heart failure and primary pulmonary hypertension$200K
- Federal grantHealth and Human S · Phase II · Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$84K
- Federal grantHealth and Human S · Phase I · Expediting the Biomarker Discovery Process Through a Novel Bead-Based Aptamer Capture Platform$300K
- Federal grantHealth and Human S · Phase II · Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation$978K
- Private capital raisedForm D · SEC · 2nd filing$950K
- Private capital raisedForm D · SEC · 1st filing$3M
Show 21 earlier federal awards
- Federal grantHealth and Human S · Phase II · Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$1.1M
- Federal grantHealth and Human S · Phase II · Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia$1.0M
- Federal grantHealth and Human S · Phase II · Aptamer therapeutic for safe and low-cost treatment of snake bite envenomation$994K
- Federal grantHealth and Human S · Phase II · Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$140K
- Federal grantHealth and Human S · Phase I · Novel inhibitor of PDE4 for the treatment of opioid use disorder$350K
- Federal grantHealth and Human S · Phase II · Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$982K
- Federal grantHealth and Human S · Phase I · Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients$225K
- Federal grantHealth and Human S · Phase I · Artificial Urethral Sphincter for Control of Urinary Incontinence in Pediatric Patients$225K
- Federal grantHealth and Human S · Phase II · Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$2.1M
- Federal grantHealth and Human S · Phase II · Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$999K
- Federal grantHealth and Human S · Phase I · Reconstituted High Density Lipoprotein Particles as siRNA Carriers$55K
- Federal grantHealth and Human S · Phase II · Preclinical evaluation of a novel small molecule STAT inhibitor$1.0M
- Federal grantHealth and Human S · Phase I · Innovative Delivery of siRNA across the Blood Brain Barrier$225K
- Federal grantHealth and Human S · Phase I · Innovative Delivery of siRNA across the Blood Brain Barrier$225K
- Federal grantHealth and Human S · Phase II · Preclinical evaluation of a novel small molecule STAT inhibitor$1.0M
- Federal grantHealth and Human S · Phase I · Uterine Wall Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$225K
- Federal grantHealth and Human S · Phase I · Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery$225K
- Federal grantHealth and Human S · Phase I · Ureteral Stent Electromagnetic Removal (USER) Device for Pediatric Patients$225K
- Federal grantHealth and Human S · Phase I · Novel Small Molecule Targeting STAT Proteins for the Management of Atopic Dermatitis$243K
- Federal grantHealth and Human S · Phase I · Novel Small Molecule Targeting STAT Proteins for the Management of Atopic Dermatitis$243K
- Federal grantHealth and Human S · Phase I · Reconstituted High Density Lipoprotein Particles as siRNA Carriers$325K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#156 · top 30%
- Granted patents#85 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Atul E. VaradhacharyResearcherExecutive Officer, DirectorLinked by $4.5M in grants as PI
- John OsborneExecutive Officer, DirectorNamed in SEC Form D filings
- Leo E. LinbeckExecutive Officer, DirectorNamed in SEC Form D filings
- Mark WorschehExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 7- GrantedAssay Device with Chambers Separated by Air GapsUSPTOUS 11,433,396
- PendingDevice For The Management Of Incontinence-related SymptomsUSPTOApplication 17557970
- PendingApproximating Anchor DeviceUSPTOApplication 17420212
Show all 7 patent records
- Assay Device with Chambers Separated by Air GapsSep 6, 2022 · US 11,433,396Granted
- Device For The Management Of Incontinence-related SymptomsJun 23, 2022 · Application 17557970Pending
- Approximating Anchor DeviceMar 3, 2022 · Application 17420212Pending
- Assay Wells with Hydrogel as a Well-Contents SeparatorSep 7, 2021 · US 11,110,459Granted
- Assay Wells with Hydrogel as a Well-Contents SeparatorAug 11, 2020 · US 10,737,270Granted
- Automated Driving of an AssayApr 9, 2019 · US 10,252,268Granted
- Aptamer-rhdl Composites For Treating DiseasesApplication PCTUS2019016132Pending
Related companies, and why
- GUIDABOT, LLCShares a founder: MICHAEL HEFFERNAN
- KANO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- METERA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- NANITE INC.Similar federal contract value in Biotech · null in contracts
- STINGRAY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- IONCOLOGI INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .